This report was first published by Endpoints News. To see the original version, click here
Ipsen extended its 18-month dealmaking streak, lining up an antibody-drug conjugate from Shanghai-based Simcere Zaiming.
Paris-based Ipsen will pay $45 million upfront for access to an antibody-drug conjugate outside of Greater China, according to a regulatory filing. The total could balloon to $1.06 billion if all milestones, including commercial ones, are met.
您已阅读33%（453字），剩余67%（940字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。